November 27, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051
Symbol: LUPIN

BSE Limited
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin Announces U.S. FDA Approval and Launch of Sitagliptin Tablets, USP in the United States".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

AMIT
KUMAR
GUPTA

Digitally signed by AMIT KUMAR GUPTA
DN: c=IN, st=Maharashtra,
2.5.4.20=f72cf02f52d2a7e595b45b84659bdca28c8f26e9390b35835a169f2a237229a3,
postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai,
pseudonym=d3a468d0d03546efabfd2a7cb7aaaae,
title=7825,
serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d70287df6aad1994f0b522fa08a, o=Personal,
cn=AMIT KUMAR GUPTA
Date: 2026.11.27 19:24:54 +05'30'

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl.: a/a.

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Lupin Announces U.S. FDA Approval and Launch of Sitagliptin Tablets, USP in the United States

Mumbai, India, Naples, Fla, November 27, 2026: Global pharma major Lupin Limited (Lupin) today announced that following the approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), the company launched Sitagliptin Tablets USP, 25 mg, 50 mg and 100 mg in the United States.

Sitagliptin Tablets USP, 25 mg, 50 mg and 100 mg, are bioequivalent to the reference listed drug (RLD), Januvia® Tablets of Merck Sharp and Dohme LLC (Merck). Sitagliptin Tablets, USP are indicated for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Sitagliptin Tablets (RLD Januvia®) had estimated annual sales of USD 2,328.8 million in the U.S. (IQVIA MAT September 2026).

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women's health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company's business strategy.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact:
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

Elise Titan
Director – U.S. Communications, Lupin
elisetitan@lupin.com

Safe Harbor Statement

Januvia is the registered trademark of Merck Sharp and Dohme LLC.